A March 23 interim final rule placed newly approved Syndros (Insys) in Schedule II (82 Fed. Reg. 14815). Comments on the rule, which took effect immediately, are due by April 24. Syndros consists of dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in oral solution. The drug was approved by the U.S. Food and Drug Administration on July 1, 2016, for the treatment o... Read More